Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

Anónimo. Blinatumomab et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:97-9. [Ref.ID 102582]

Anónimo. Pégaspargase et leucémie aiguë lymphoblastique. Prescrire 2017;37:249-51. [Ref.ID 101530]

Anónimo. Crisantaspase et leucémie aiguë lymphoblastique. Prescrire 2017;37:247-9. [Ref.ID 101529]

Kantarijian HM, DeAngelo DJ, Stellijes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumb ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-53. [Ref.ID 100716]

Anónimo. Ponatinib. Prescrire 2015;35:176-81. [Ref.ID 98925]

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz PG, Jurcic J, Rosenblat T, Masiak P, Frattini M, Sadelain M. CD19-targeted cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177. [Ref.ID 95067]

Anónimo. Romiplostim: leucémies après syndromes myélodysplasiques. Prescrire 2011;31:910. [Ref.ID 91886]

Anónimo. Lenalidomide (Revlimid): risk of secondary primary malignancy - update. Drug Safety Update 2011;5:1-2. [Ref.ID 91625]

Sipkins DA. Rendering the leukemia cell susceptible to attack. N Engl J Med 2009;361:1307-9. [Ref.ID 86823]

Dombret H, Gardin C. An old AML drug revisited. N Engl J Med 2009;361:1301-3. [Ref.ID 86822]

Fernández HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59. [Ref.ID 86819]

Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G, for the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) German AML Study Group (AMLSG) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48. [Ref.ID 86818]

Mitchell C, Hall G, Clarke RT. Acute leukaemia in children: diagnosis and management. BMJ 2009;338:1491-5. [Ref.ID 86088]

Anónimo. Enrichir sa panoplie thérapeutique. Bilan de l'année 2008. Pédiatrie. Prescrire 2009;29:49-50. [Ref.ID 84824]

Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM, on behalf of investigators of QUIT Study (PETHEMA GELTAMO and GOTEL Groups). Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc) 2008;131:401-5. [Ref.ID 84143]

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HGM. Predictors of orphan drug approval in the European Union. Eur J Clin Pharmacol 2008;64:545-52. [Ref.ID 82991]

Anónimo. Facteurs de croissance granulocytaire: hémopathies malignes. Prescrire 2008;28:351-3. [Ref.ID 82821]

Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li C-K, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240-50. [Ref.ID 80624]

Ribera J-M, Oriol A. A step forward in therapy for ALL in infants. Lancet 2007;370:198-200. [Ref.ID 80612]